North America Malaria Treatment Market

The North America malaria treatment market was valued at US$ 62.97 million in 2022 and is expected to reach US$ 487.31 million by 2030; it is estimated to grow at a CAGR of 29.1% from 2022 to 2030. 

Increasing Prevalence of Malaria Fuels North America Malaria Treatment Market

Malaria, one of the acute febrile illnesses, is caused by plasmodium parasites and spreads through the infected female Anopheles mosquitoes. Five parasite species in humans mainly cause malaria, and two of these species-Plasmodium falciparum and P. vivax-are considered the greatest threat to human health. Also, P. falciparum is the deadliest malarial parasite, and it is most widely spread across the African continent. Further, P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa. According to the latest World Malaria Report (WMR) 2020 from the World Health Organization (WHO), 241 million cases of malaria were reported in the world, in comparison to 227 million cases that were logged in 2019. According to the same source, the number of deaths caused due to malaria has an annual rise of 69,000 deaths. Approximately two-thirds of these deaths, i.e., 47,000, were caused by disruptions in healthcare services during the COVID-19 outbreak; the remaining one-third of deaths, i.e., 22,000 reflected a recent change in the WHO's methodology for calculating malaria mortality (irrespective of COVID-19 disruptions). Thus, the rising prevalence of malaria boosts the malaria treatment market growth. 

North America Malaria Treatment Market Overview

According to the Centers for Disease Control and Prevention (CDC), approximately 2,000 cases of malaria are reported annually in the US, mostly in travelers from other countries and immigrants. Pregnant women and children under 5 years of age are at the highest risk of contracting malaria and developing severe diseases. There is a perpetual risk that malaria transmission can resume in the US due to the endurance of anopheles mosquitoes (vectors) capable of transmitting malaria in the US. According to the Global Fund data from April 2022, cases and deaths related to malaria rose mainly due to stalled funding and disruptions caused by the COVID-19 pandemic. However, efforts to moderate these impacts have seen progress, as mentioned in the Global Fund report in September 2022. Efforts taken by the US government to control malaria include activities primarily through the US President's Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator. According to Global Health Policy, US funding for malaria control and research activities was approximately US$ 1 billion in FY 2022. The US government's goal under the PMI Strategy 2021-2026 is to work and reduce deaths caused by malaria and decrease malaria morbidity, in turn approaching its long-term goal of elimination.

Thus, the malaria treatment market growth in the US is driven by the rising number of malaria patients.

North America Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Malaria Treatment Strategic Insights

Strategic insights for the North America Malaria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Malaria Treatment Report Scope

North America Malaria Treatment Regional Insights

The geographic scope of the North America Malaria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Malaria Treatment Market Segmentation

The North America malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the North America malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022. 

In terms of route of administration, the North America malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022. 

By distribution channel, the North America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. 

Based on country, the North America malaria treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America malaria treatment market share in 2022. 

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are some of the leading players operating in the North America malaria treatment market.